3. Program Goals

4. Introduction

5. Case 1: A 44-Year-Old Woman

6. Definition of High-Risk Melanoma

7. Trials of High-Dose Interferon-Alfa

8. Toxicity Profile of Interferon-Alfa

9. Ipilimumab: EORTC 18071 Study Design

10. Ipilimumab: EORTC 18071 Efficacy Data

11. Ipilimumab: EORTC 18071 Safety Data

12. US Intergroup E1609 Study Design

13. Phase 3 Adjuvant Therapy Trials

14. Case 1: Conclusion

15. Neoadjuvant Therapy Trials

16. Case 2: A 54-Year-Old Man

17. Case 2: Treatment Options

18. Ipilimumab in Metastatic Melanoma

19. KEYNOTE-006: Study Design and Data

20. CheckMate 037 Trial of Nivolumab

21. CheckMate 067 and 069 Trials

22. Combined BRAF and MEK Inhibitors

23. Pembrolizumab in BRAF+ Melanoma

24. ECOG-ACRIN EA16134 Study Design

25. Conclusions on Anti-PD1 Antibodies

26. Brain Metastases in Melanoma

27. BREAK-MB: Phase 2 Trial of Dabrafenib

28. Case 3: A 65-Year-Old Man

29. Case 3: Managing the Patient's Colitis

30. Case 3: Steroid Taper

31. Managing Immune-Related AEs

32. Immunotherapy-Related Endocrinopathy

33. Management of Endocrinopathies

34. Common AEs With PD1 Inhibitors

35. Abbreviations

36. Abbreviations (cont)

37. Abbreviations (cont)

38. Abbreviations (cont)